JP4733270B2 - インターロイキン−１−βインヒビターとしての置換されたチアジアゾールスルホンアミド - Google Patents

インターロイキン−１−βインヒビターとしての置換されたチアジアゾールスルホンアミド Download PDF

Info

Publication number
JP4733270B2
JP4733270B2 JP2000577158A JP2000577158A JP4733270B2 JP 4733270 B2 JP4733270 B2 JP 4733270B2 JP 2000577158 A JP2000577158 A JP 2000577158A JP 2000577158 A JP2000577158 A JP 2000577158A JP 4733270 B2 JP4733270 B2 JP 4733270B2
Authority
JP
Japan
Prior art keywords
alkyl
phenyl
substituted
unsubstituted
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000577158A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002527510A5 (https=
JP2002527510A (ja
Inventor
ヴェルナー・トーアヴァルト
クラウス−ウルリヒ・ヴァイトマン
スヴェン・ヘルダー
Original Assignee
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2002527510A publication Critical patent/JP2002527510A/ja
Publication of JP2002527510A5 publication Critical patent/JP2002527510A5/ja
Application granted granted Critical
Publication of JP4733270B2 publication Critical patent/JP4733270B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2000577158A 1998-10-16 1999-10-02 インターロイキン−１−βインヒビターとしての置換されたチアジアゾールスルホンアミド Expired - Fee Related JP4733270B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19847823A DE19847823A1 (de) 1998-10-16 1998-10-16 Substituierte Thiadiazolsulfonamide
DE19847823.2 1998-10-16
PCT/EP1999/007301 WO2000023430A1 (de) 1998-10-16 1999-10-02 Substituierte thiadiazolsulfonamide als interleukin-1-beta-hemmer

Publications (3)

Publication Number Publication Date
JP2002527510A JP2002527510A (ja) 2002-08-27
JP2002527510A5 JP2002527510A5 (https=) 2011-03-10
JP4733270B2 true JP4733270B2 (ja) 2011-07-27

Family

ID=7884736

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000577158A Expired - Fee Related JP4733270B2 (ja) 1998-10-16 1999-10-02 インターロイキン−１−βインヒビターとしての置換されたチアジアゾールスルホンアミド

Country Status (11)

Country Link
US (2) US6218412B1 (https=)
EP (1) EP1121349B1 (https=)
JP (1) JP4733270B2 (https=)
AR (1) AR023909A1 (https=)
AT (1) ATE263158T1 (https=)
AU (1) AU6088799A (https=)
DE (2) DE19847823A1 (https=)
DK (1) DK1121349T3 (https=)
ES (1) ES2214885T3 (https=)
PT (1) PT1121349E (https=)
WO (1) WO2000023430A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US7851418B2 (en) * 2005-06-03 2010-12-14 Exxonmobil Research And Engineering Company Ashless detergents and formulated lubricating oil containing same
WO2009021052A1 (en) * 2007-08-06 2009-02-12 University Of Kentucky Research Foundation Polypeptides, systems, and methods useful for detecting glucose
RU2434856C1 (ru) * 2010-10-15 2011-11-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) 5-амино-3-(2-нитроксипропил)-1,2,4-тиадиазолы
EP2628734A4 (en) * 2010-10-15 2014-04-23 Federalnoe G Bydzhetnoe Uchrezhdenie Nauki Inst Fiziol Aktivnikh Veschestv Rossiiskoi Akademii Nauk DERIVATIVES OF 5-AMINO - [1,2,4] THIADIAZOLE
CA2877026A1 (en) * 2012-05-18 2013-11-21 Amgen Inc. Method for the preparation of thiadiazoles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873239A (en) 1987-01-29 1989-10-10 Hoechst-Roussel Pharmaceuticals, Inc. Arylthiadiazolylsulfonamides and derivatives
US4985450A (en) 1987-01-29 1991-01-15 Tegeler John J Arylthiadiazolylsulfonamides and derivatives
US4758578A (en) * 1987-01-29 1988-07-19 Hoechst Roussel Pharmaceuticals, Inc. Arylthiadiazolylsulfonamides, pharmaceutical compositions and use
ES2124800T3 (es) 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
AU702887B2 (en) * 1995-10-31 1999-03-11 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
EP0900791A1 (en) * 1995-12-27 1999-03-10 Ono Pharmaceutical Co., Ltd. Tetrazole derivatives and drugs containing the same as the active ingredient
JPH09235276A (ja) * 1995-12-27 1997-09-09 Takeda Chem Ind Ltd オキサゾール誘導体、その製造法および用途
KR20000057137A (ko) * 1996-11-19 2000-09-15 스티븐 엠. 오드레 아릴 및 헤테로아릴로 치환된 융합 피롤 항염증제

Also Published As

Publication number Publication date
ES2214885T3 (es) 2004-09-16
DE19847823A1 (de) 2000-04-20
US6503934B2 (en) 2003-01-07
ATE263158T1 (de) 2004-04-15
AU6088799A (en) 2000-05-08
DK1121349T3 (da) 2004-07-12
JP2002527510A (ja) 2002-08-27
EP1121349B1 (de) 2004-03-31
US20010039350A1 (en) 2001-11-08
DE59909049D1 (en) 2004-05-06
AR023909A1 (es) 2002-09-04
WO2000023430A1 (de) 2000-04-27
US6218412B1 (en) 2001-04-17
EP1121349A1 (de) 2001-08-08
PT1121349E (pt) 2004-08-31

Similar Documents

Publication Publication Date Title
AU2023201669B2 (en) Compositions and methods for modulating hair growth
JP4855368B2 (ja) 代謝調節剤として有用なマロニル−ＣｏＡ脱炭酸酵素阻害剤
KR101262400B1 (ko) 아미노카르복실산 유도체 및 그 의약 용도
KR101186386B1 (ko) Ｓ１ｐ 수용체 결합능을 갖는 화합물 및 그 의약 용도
JP4871257B2 (ja) ２−フェニルプロピオン酸誘導体およびそれらを含有する医薬組成物
PH12015502708B1 (en) Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
MX2013003345A (es) Compuesto de amida sustituida.
RU2263113C2 (ru) Производные 8,8а-дигидроиндено [1,2-d]тиазола, содержащие в положении 2 заместитель с сульфонамидной или сульфоновой структурой, способ их получения и их применение в качестве лекарственного средства
US6395730B1 (en) Potassium channel inhibitors
WO2009117335A2 (en) S1p3 receptor inhibitors for treating inflammation
JP4733270B2 (ja) インターロイキン−１−βインヒビターとしての置換されたチアジアゾールスルホンアミド
JP2018527354A (ja) ６員アザヘテロ環を含有するデルタ−オピオイド受容体調節化合物、同化合物を使用する方法、および同化合物を作る方法
CA2152401C (fr) Association synergisante ayant un effet antagoniste des recepteurs nk1 et nk2
US20060014740A1 (en) Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof
MXPA06005528A (es) Tiazolidinona-amidas, amidas de acido tiazolidina-carboxilico, metodos de elaboracion, y uso de las mismas.
EP1097159A1 (de) Phosphin- und phosphonsäurederivate als arzneimittel
JP4486363B2 (ja) 置換３−フェニル−５−アルコキシ−１，３，４−オキサジアゾール−２−オン、これの製造方法および薬剤での使用
US6174908B1 (en) Potassium channel inhibitors
WO2005086638A2 (en) Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof
JPWO2001000613A1 (ja) ベンズイミダゾール化合物及びそれを含む医薬
RU2263669C2 (ru) Замещенные 8,8a-дигидро-3ah-индено [1,2-d] тиазолы, способ их получения и их применение в качестве лекарственных средств
DE19831980A1 (de) Sulfonylaminophosphin- und phosphonsäurederivate
CA3085233A1 (en) Compounds for the treatment of neuromuscular disorders
EA040399B1 (ru) Соединения для лечения эпилепсии, нейродегенеративных нарушений и других нарушений цнс
MXPA01002663A (en) Oxazole compounds as prostaglandin e2 agonists or antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060929

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100330

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100625

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20100625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101019

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110119

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110422

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140428

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees